Inclusion Criteria:

- Histologically and cytologically confirmed malignant mesothelioma of the pleura

- All subtypes allowed

- Disease not amenable to curative surgery

- Measurable disease

- Patients with disease not measurable by standard RECIST criteria (i.e., pleural
rinds/thickening only) allowed

- Pleural effusions or positive bone scans are not considered measurable

- No prior radiotherapy to the target lesion or measurable lesion unless the site has
subsequent evidence of progression

- Patients who have undergone pleurodesis allowed

- Post-pleurodesis CT scan required

- No known or suspected brain metastases

- ECOG performance status 0-1

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 1.5 times ULN

- ALT and AST ≤ 1.5 times ULN

- Albumin ≥ 2.5 g/dL

- Creatinine clearance ≥ 45 mL/min OR serum creatinine ≤ 1.5 times ULN

- Able to take folic acid and vitamin B12

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must agree to use effective contraception

- No active infection or serious concomitant systemic disorder in compatible with the
study

- No thrombosis or vascular ischemic events within the last 12 months, including any of
the following:

- Deep venous thrombosis

- Pulmonary embolism

- Transient ischemic attack

- Cerebral infarction

- Myocardial infarction

- No peripheral edema ≥ grade 3

- No serious or non-healing wounds

- No second primary malignancy except in situ carcinoma of the cervix or breast, other
in situ malignancies, adequately treated basal cell carcinoma of the skin, or other
malignancy within the past 3 years with no evidence of recurrence

- No concurrent antiretroviral therapy for HIV-positive patients

- At least 4 weeks since prior radiotherapy

- More than 30 days since major surgery procedures or > 14 days since any minor
surgical procedure and recovered

- Central venous catheter placement, fine-needle aspiration, thoracentesis, or
paracentesis are not considered major or minor surgical procedures

- No prior systemic chemotherapy for mesothelioma

- No prior intracavity cytotoxic drugs or immunomodulators (unless for the purpose of
pleurodesis)

- No prior anti-HGF monoclonal antibody AMG 102, other c-MET, or HGF inhibitors

- No prior or concurrent anticoagulation therapy within the past 7 days

- Low-dose Coumadin-type anticoagulants or low-molecular weight heparin for
prophylaxis against central venous catheter thrombosis allowed

- No investigational agents within the past 4 weeks